Stage IIIB Skin Melanoma Withdrawn Phase 1 / 2 Trials for Imatinib (DB00619)
| Indication | Status | Phase |
|---|---|---|
| DBCOND0029534 (Stage IIIB Skin Melanoma) | Withdrawn | 1 / 2 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT02812693 | Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification | Treatment |